Rhumbline Advisers Sells 1,713 Shares of Mesoblast Limited (NASDAQ:MESO)

Rhumbline Advisers reduced its position in shares of Mesoblast Limited (NASDAQ:MESO) by 15.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,342 shares of the company’s stock after selling 1,713 shares during the quarter. Rhumbline Advisers’ holdings in Mesoblast were worth $185,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Strategic Financial Concepts LLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $2,744,000. Jane Street Group LLC grew its stake in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the period. Clayton Financial Group LLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $275,000. Ballentine Partners LLC bought a new stake in shares of Mesoblast during the 4th quarter valued at about $222,000. Finally, Creative Planning bought a new stake in shares of Mesoblast during the 3rd quarter valued at about $147,000. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Stock Down 3.0 %

MESO stock opened at $13.07 on Tuesday. Mesoblast Limited has a twelve month low of $2.05 and a twelve month high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The business’s 50-day moving average price is $17.77 and its 200-day moving average price is $12.47.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald upgraded Mesoblast to a “strong-buy” rating in a research note on Tuesday, March 4th. Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Mesoblast currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.